Oncolytics Biotech (TSE:ONC) Director Buys C$46,800.00 in Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Bernd Robert Seizinger bought 40,000 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were acquired at an average cost of C$1.17 per share, for a total transaction of C$46,800.00. Following the completion of the acquisition, the director directly owned 566,991 shares of the company’s stock, valued at C$663,379.47. This trade represents a 7.59% increase in their position.

Bernd Robert Seizinger also recently made the following trade(s):

• On Wednesday, February 11th, Bernd Robert Seizinger acquired 60,000 shares of Oncolytics Biotech stock. The shares were bought at an average price of C$1.14 per share, for a total transaction of C$68,400.00.

Oncolytics Biotech Stock Performance

The firm has a fifty day moving average of C$14.90 and a 200 day moving average of C$13.02. Oncolytics Biotech Inc. has a one year low of C$0.44 and a one year high of C$2.08. The company has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. On average, analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.